Recent

% | $
Quotes you view appear here for quick access.

Exact Sciences Corporation Message Board

  • netstockreader netstockreader Sep 9, 2010 12:33 PM Flag

    Valuation? October 29th Validation?

    "The Senior Research Analyst for Life Sciences / Diagnostics, Quintin J. Lai, Ph.D., CFA, of Robert W. Baird was also on the call asking questions and previously followed Third Wave from its early stages of development. Analyst coverage for EXAS is likely to occur well ahead of its planned FDA clinical trial and 510(k) de novo filing given the huge unmet medical need for an effective mass screening tool for CRC and the large commercial opportunity – including a market of about 90 million people in the U.S. alone that would represent over $1 billion with a 30% penetration rate according to the Company’s estimates."

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
EXAS
24.51-0.39(-1.57%)Jul 29 4:00 PMEDT